文献速递认知障碍与谵妄多重用药老年综合评估

澳大利亚痴呆与非痴呆老年人的高风险处方:全国横断面研究

High-Risk Prescribing in Older People With and Without Dementia in Australia: A Nationwide Cross-Sectional Study.
PubMed 文献 · J Am Med Dir Assoc · 2025-12-05

该全国横断面研究基于2021年人口普查与药品福利计划链接数据,分析≥65岁澳大利亚老年人中痴呆与非痴呆者的高风险处方情况。结果显示痴呆患者高风险处方患病率(82.7%)高于非痴呆者(65.4%),且高风险处方与居住非私人住宅、核心活动需协助及合并症多相关,高教育、高社会经济地位及文化语言多样性背景者风险较低。

要点

  • 痴呆老年人高风险处方患病率82.7%,高于非痴呆者的65.4%。
  • 高风险处方包括潜在不适当用药、多重用药(≥5种)、抗胆碱能药和镇静药。
  • 居住非私人住宅、核心活动需协助、合并症多增加高风险处方可能。

核心结论

  • 痴呆患者中高风险处方常见,且随社会人口学因素变化,需定期针对性药物审查。

研究设计与样本

  • 全国横断面研究,纳入2021年人口普查与药品福利计划链接数据中≥65岁澳大利亚老年人3,850,281名。

主要发现

  • 痴呆患者177,809名(4.6%),其高风险处方患病率为82.7%,非痴呆者为65.4%。
  • 痴呆与非痴呆者高风险处方患病率差异在较年轻年龄组最大,随年龄增长逐渐缩小。
  • 居住非私人住宅、核心活动需协助及合并症更多者高风险处方可能性增加。
  • 较高教育、较高社会经济地位及文化语言多样性背景与较低高风险处方可能性相关。

关键数值与推荐

  • 高风险处方定义:使用2023 Beers标准或2024澳大利亚PIMs列表中的潜在不适当用药、多重用药(≥5种药物)、抗胆碱能药和镇静药(基于药物负担指数和抗胆碱能认知负担量表)。
  • 痴呆定义:人口普查自报或药品福利计划配发胆碱酯酶抑制剂/美金刚。

临床怎么用

  • 对痴呆老年人应定期进行针对性药物审查,关注潜在不适当用药、多重用药及抗胆碱能/镇静药物负担。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Older people, especially those living with dementia, are susceptible to drug-related problems. This study aimed to calculate the national prevalence and identify factors associated with high-risk prescribing in older people with and without dementia living in Australia. DESIGN: A nationwide cross-sectional study. SETTING AND PARTICIPANTS: Older Australians (≥65 years) using linked 2021 Census and Pharmaceutical Benefits Scheme data. METHODS: Medication use was defined as dispensing during the 3-month period following the Census (August-October 2021). High-risk prescribing included use of potentially inappropriate medications [2023 Beers Criteria and 2024 Australian potentially inappropriate medications (PIMs) list], polypharmacy (≥5 medications), and anticholinergics and sedatives (medications contributing to the Drug Burden Index and the Anticholinergic Cognitive Burden scale). Dementia was defined by self-report in Census or Pharmaceutical Benefits Scheme-dispensed cholinesterase inhibitor/memantine. Sociodemographic factors associated with high-risk prescribing were explored with logistic regression models. RESULTS: Among 3,850,281 individuals, 177,809 (4.6%) had dementia. People with dementia had a higher prevalence of high-risk prescribing (82.7%) compared with those without dementia (65.4%). Among individuals with dementia, the difference in high-risk prescribing prevalence compared with those without dementia was greatest in the younger age groups and progressively narrowed in the oldest age groups. Residing in nonprivate dwellings, requiring assistance with core activities, and having more comorbidities increased the likelihood of high-risk prescribing. Higher education, socioeconomic status, and culturally and linguistically diverse backgrounds were linked to lower likelihood. CONCLUSIONS AND IMPLICATIONS: High-risk prescribing is common in those living with dementia and varies by sociodemographic factors. Regular, targeted medication reviews are needed to ensure quality use of medicines in this population.

来源:J Am Med Dir Assoc,查看原文。版权归原作者所有。

引用

  1. Lau ECY, Chen W, Hilmer SN, et al. High-Risk Prescribing in Older People With and Without Dementia in Australia: A Nationwide Cross-Sectional Study. J Am Med Dir Assoc. 2025. PMID: 41271192. doi:10.1016/j.jamda.2025.106006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。